ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,251.90
-0.68%
S&P ASX All Technology
3,847.50
-1.41%
Brent Oil
74.075
-0.55%
US Dollar vs AUD
1.57721
-0.04%
Bitcoin
89,178.77
-2.48%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Keros Therapeutics Inc (KROS) Share Price

Keros Therapeutics Inc

Keros Therapeutics Inc (KROS)

NASDAQ
10.79
-0.23
(-2.09%)
Closed 25 February 8:00AM
Delayed by 15 minutes
10.79
0.00
( 0.00% )
Pre Market: 10:39PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
10.79
Bid
10.71
Offer
11.25
Volume
67
0.00 Day's Range 0.00
9.775 52 Week Range 73.00
Market Cap
437.075M
Previous Close
10.79
Open
-
Last Trade
1
@
10.79
Last Trade Time
21:59:41
Financial Volume
-
VWAP
-
Average Volume (3m)
1,729,066
Shares Outstanding
40,507,409
Dividend Yield
-
PE Ratio
-2.86
Earnings Per Share (EPS)
-3.78
Revenue
151k
Net Profit
-152.99M

About Keros Therapeutics Inc

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candida... Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.kerostx.com
Headquarters
Dover, Delaware, USA
Founded
-
Keros Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KROS. The last closing price for Keros Therapeutics was US$10.79. Over the last year, Keros Therapeutics shares have traded in a share price range of US$ 9.775 to US$ 73.00.

Keros Therapeutics currently has 40,507,409 shares in issue. The market capitalisation of Keros Therapeutics is US$437.07 million. Keros Therapeutics has a price to earnings ratio (PE ratio) of -2.86.

Ask ADVFN Intelligence (AI)

KROS Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
20 February 2025
KROS (-2.09%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
20 February 2025
KROS (-2.09%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
20 February 2025
KROS (-2.09%)

Form 8-K - Current report
Edgar (US Regulatory)
31 January 2025
KROS (-2.09%)

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
Edgar (US Regulatory)
25 January 2025
KROS (-2.09%)

Form 8-K - Current report
Edgar (US Regulatory)
22 January 2025
KROS (-2.09%)

Form 8-K - Current report
Edgar (US Regulatory)
15 January 2025
KROS (-2.09%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.2051.9367028814410.58511.210.4383600310.81428926CS
4-0.65-5.6818181818211.4412.0510.0999955410.94759429CS
12-45.85-80.949858757156.6472.379.775172906615.94288827CS
26-35.1-76.487252124645.8972.379.77596126224.78084506CS
52-52.62-82.983756505363.41739.77564946232.7353634CS
156-41.36-79.30968360552.15739.77537530136.8747072CS
260-9.31-46.318407960220.188.89.77528396439.67394345CS

KROS - Frequently Asked Questions (FAQ)

What is the current Keros Therapeutics share price?
The current share price of Keros Therapeutics is US$ 10.79
How many Keros Therapeutics shares are in issue?
Keros Therapeutics has 40,507,409 shares in issue
What is the market cap of Keros Therapeutics?
The market capitalisation of Keros Therapeutics is USD 437.07M
What is the 1 year trading range for Keros Therapeutics share price?
Keros Therapeutics has traded in the range of US$ 9.775 to US$ 73.00 during the past year
What is the PE ratio of Keros Therapeutics?
The price to earnings ratio of Keros Therapeutics is -2.86
What is the cash to sales ratio of Keros Therapeutics?
The cash to sales ratio of Keros Therapeutics is 2.92k
What is the reporting currency for Keros Therapeutics?
Keros Therapeutics reports financial results in USD
What is the latest annual turnover for Keros Therapeutics?
The latest annual turnover of Keros Therapeutics is USD 151k
What is the latest annual profit for Keros Therapeutics?
The latest annual profit of Keros Therapeutics is USD -152.99M
What is the registered address of Keros Therapeutics?
The registered address for Keros Therapeutics is 850 NEW BURTON ROAD, SUITE 201, DOVER, DELAWARE, 19904
What is the Keros Therapeutics website address?
The website address for Keros Therapeutics is www.kerostx.com
Which industry sector does Keros Therapeutics operate in?
Keros Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
FMTOFemto Technologies Inc
US$ 7.59
(112.21%)
5.42M
BREABrera Holdings PLC
US$ 1.20
(90.08%)
24.28M
WAFUWah Fu Education Group Ltd
US$ 3.18
(77.65%)
10.36M
MBRXMoleculin Biotech Inc
US$ 1.85
(72.90%)
11.62M
MFImF International Ltd
US$ 0.998
(66.42%)
9.44M
KTCCKeyTronic Corporation
US$ 2.00
(-35.48%)
345
CFSBCFSB Bancorp Inc
US$ 5.01
(-34.60%)
135
YYAIConnexa Sports Technologies Inc
US$ 0.84
(-33.86%)
570.25k
STECSantech Holdings Limited
US$ 1.16
(-28.83%)
642.64k
TWFGTWFG Inc
US$ 20.75
(-27.40%)
15
DMNDamon Inc
US$ 0.3951
(30.01%)
28.14M
BREABrera Holdings PLC
US$ 1.20
(90.08%)
24.28M
MBRXMoleculin Biotech Inc
US$ 1.85
(72.90%)
11.62M
WAFUWah Fu Education Group Ltd
US$ 3.18
(77.65%)
10.36M
MFImF International Ltd
US$ 0.998
(66.42%)
9.44M

KROS Discussion

View Posts
TheFinalCD TheFinalCD 1 month ago
$KROS halts all dosing in the TROPOS Phase 2 clinical trial of cibotercept (KER-012) based on the ongoing safety review due to new observations of pericardial effusion adverse events

https://x.com/BioStocks/status/1879492237891080688

$KROS the TROPOS trial is being terminated early. The Co continues to expect to present topline data from all treatment arms in this trial in Q2
https://x.com/BioStocks/status/1879493199288586404
👍️0
retireat40 retireat40 2 months ago
Wow. What a turd 
👍️0
retireat40 retireat40 2 months ago
Shocked this is still sub 18
👍️0
Dennis14 Dennis14 2 months ago
Bought in at 18.00
👍️0
Monksdream Monksdream 5 months ago
KROS more upside possible

👍️0
Monksdream Monksdream 1 year ago
KROS new 52=week high
👍️0

Your Recent History

NASDAQ
KROS
Keros Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads